Updates are available Correction dated 2020-01-22

Article History

Received: 13 June 2019

Accepted: 4 September 2019

First Online: 3 December 2019

Change Date: 22 January 2020

Change Type: Correction

Change Details: After the publication of this work [1] the authors have reported that in Table 3 The letter “T” in columns 5 and 7 should not be there.

Ethics approval and consent to participate

: The study protocol was approved by the Institutional Review Boards of each participating institution, and all patients provided written informed consent. The study was conducted according to the Good Clinical Practice and the Declaration of Helsinki and its amendments. The authors had full control of all primary data.

: Not applicable.

: Dr. Pérez-Garcia reports advisory roles with Roche/Lilly/MedSIR.Dr. Cortes reports the following: consulting/advisor: Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics Daiichi Sankyo, Erytech, and Athenex; honoraria: Roche, Novartis, Celgene, Eisai, Pfizer, and Samsung; <b>r</b>esearch funding to institution: Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F.Hoffman-La Roche, Guardant health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C, and Queen Mary University of London; and stock, patents, and intellectual property: MedSIRDr. Di Cosimo reports the following: Speaker’s Bureau: Novartis Pharma.Dr. La Verde reports the following conflicts of interest: Pfizer, Eisai, Roche, Novartis, Celldex, and TEVA.Dr. Lucas reports stock ownership in Amgen and consulting activity with Bayer/Loxo.All other authors declare that they have no competing interests.